


LEGEND-T2DM Evidence Dissemination Summary

Target: **saxagliptin**, Comparator: **sitagliptin** Outcome: **Joint pain**

How Often? (Incidence rates in the PS-matched target cohorts)

| Data source | Persons exposed | Person-time (yrs) | Persons with outcome | IR (/1,000 PY) |
|---------------------|-----------------|-------------------|----------------------|----------------|
| IQVIA DA Germany | 1,009 | 1,176 | 24 | 20.41 |
| IQVIA LDP France | - | - | - | - |
| IQVIA Open Claims | - | - | - | - |
| Merative CCAE | 10,971 | 8,523 | 87 | 10.21 |
| Merative MDCCD | - | - | - | - |
| Merative MDCR | 1,365 | 1,240 | 71 | 57.27 |
| Optum Clinformatics | 7,565 | 6,396 | 245 | 38.31 |
| Optum EHR | 5,944 | 2,099 | 24 | 11.44 |
| Veterans Affairs | 3,869 | 3,745 | 33 | 8.81 |

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

